Position in COLL
as of Jun 30, 2026
· filed Jul 31, 2026
Position Value
$217
New position
Shares Held
6
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#271
of 277 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Evolution Advisers, Inc. holds $2,645 across 10 Drug Manufacturers - Specialty & Generic names. COLL ranks #5 (8.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALKS |
Alkermes plc.
|
19 | $995 | |
| 2 | PRGO |
PERRIGO Co plc
|
26 | $270 | |
| 3 | ANIP |
Ani Pharmaceuticals Inc
|
3 | $248 | |
| 4 | SUPN |
Supernus Pharmaceuticals, Inc.
|
5 | $232 | |
| 5 | COLL |
Collegium Pharmaceutical, Inc
This page
|
6 | $217 | |
| 6 | NBIX |
Neurocrine Biosciences Inc
|
1 | $168 | |
| 7 | PCRX |
Pacira BioSciences, Inc.
|
6 | $152 | |
| 8 | VTRS |
Viatris Inc
|
9 | $142 |
All Filings in COLL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $217 | 6 | Shares | Sole | 2026-07-31 | |
| No filing history on record for this holder in this stock. | ||||||